Invasive Fungal Disease
Conditions
Keywords
invasive fungal infection, Web-based registry
Brief summary
The objective of this registry is to broaden the knowledge on epidemiology, diagnostic procedures and clinical course of emerging invasive fungal infections.
Detailed description
The specific objectives are: 1. To determine the fungal species causing invasive fungal infection in different parts of the world. 2. To determine the clinical pattern of disease and document procedures performed for confirmation of the diagnosis. 3. To describe the therapeutic regimens used and their efficacy. 4. To share clinical isolates among the contributors of Fungiscope. 5. To develop molecular biology tools for identification of strains in histopathologically proven invasive fungal infection.
Interventions
None listed
Sponsors
Pfizer
Basilea Pharmaceutica
Cidara Therapeutics Inc.
F2G Biotech GmbH
Matinas Biopharma, Inc
University of Cologne
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Cultural, histopathological, antigen or DNA evidence of invasive fungal infection
Exclusion criteria
* Infection due to Candida spp., Cryptococcus neoformans, Pneumocystis jiroveci * Endemic fungal infection such as coccidioidomycosis or histoplasmosis * Colonisation or other non-invasive infection
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Treatment efficacy of emerging fungal infections | At 90 days from diagnosis | failure, stable disease, partial response or complete response |
Countries
Germany
Contacts
Primary ContactOliver A Cornely, Prof.
Outcome results
None listed